Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-1905 injection in severe uncontrolled asthma
CTR20222535Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SHR-1905 in asthma (6 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Annualized asthma exacerbation rate. Started Feb 2023; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20222535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222535.